Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

Safety and Efficacy of Initializing the Control-IQ Artificial Pancreas System Using Total Daily Insulin

NCT03804983 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this proposed study is to assess the use of a new feature of the Control-IQ system, MyTDI.

Conditions Studied

Interventions

  • DEVICE Hybrid Closed Loop (HCL)
  • DEVICE Control-IQ with MyTDI

Study Locations (1)

Virginia

  • University of Virginia Center for Diabetes Technology — Charlottesville

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2019-01-15
Est. Completion 2019-02-16
Phase NA

Sponsor

University of Virginia

392 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03804983

The ClinicalTrials.gov registry entry for NCT03804983 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Virginia, which has 392 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Type 1 Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions — of which Hybrid Closed Loop (HCL) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT03804983 reports 1 study location spanning 1 distinct geographic area — top geographies include Virginia. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT03804983 about?

NCT03804983 is a clinical study titled "Safety and Efficacy of Initializing the Control-IQ Artificial Pancreas System Using Total Daily Insulin". The purpose of this proposed study is to assess the use of a new feature of the Control-IQ system, MyTDI.

What is the current status of trial NCT03804983?

This trial is currently completed. It is a NA study. The enrollment target is 22 participants. The study started on 2019-01-15. Estimated completion is 2019-02-16.

What conditions does trial NCT03804983 study?

This clinical trial studies the following conditions: Type 1 Diabetes Mellitus. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT03804983?

The interventions under investigation include: Hybrid Closed Loop (HCL) (DEVICE), Control-IQ with MyTDI (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT03804983?

This trial is sponsored by University of Virginia, which has 392 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT03804983 being conducted?

This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial